摘要：The return of Plasmodium falciparum strains that are sensitive to chloroquine (CQ) in some parts of Africa and the si-
multaneous development of its resistance to artemisinin and artemisinin combination therapy (ACT) in some south east
Asian countries is prompting researchers to reevaluate probable evidence for the re-introduction of these former antimalar-
ial drugs should P. falciparum parasite develop resistance to ACTs in Africa. This becomes much more the glaring option
(re-introduction of former antimalarials) since there is no alternative first-line drug against P. falciparum , although so many
are in different clinical trial phase.
